Gilead Sciences (GILD) reported the results of an interim analysis from a second Phase 3 clinical trial investigating the use of the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence. At interim analysis, the independent Data Monitoring Committee confirmed that the PURPOSE 2 trial met its key efficacy endpoints of superiority of twice-yearly lenacapavir to both bHIV and once-daily oral Truvada for pre-exposure prophylaxis. The DMC recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.
The company said the data from the PURPOSE 1 and PURPOSE 2 trials will support upcoming regulatory filings.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.